Vor Bio, a clinical-stage biotech company, granted stock options for 61,050 shares and RSUs for 12,900 shares to 10 newly hired employees as inducements to employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the company's 2023 Inducement Plan. The stock options have a 10-year term with an exercise price of $14.57, vesting over four years, while the RSUs also vest over four years. This move aims to attract and retain talent as Vor Bio advances its autoimmune disease treatments, including its lead drug telitacicept in late-stage clinical trials.
A study by i10X Research reveals significant bias in AI-driven job application evaluations, where identical resumes written by different AI models receive vastly different hire recommendations. The study analyzed 100 candidate profiles across four AI...
Adswerve has been selected as a North American partner for Google's new GCS Implementation Partner (GIP) program, part of the Data Strength Partner Program. This partnership helps brands improve first-party data infrastructure to recover lost convers...
In 2026, five small-cap stocks in the Russell 2000 index have each gained more than 400%, significantly outperforming major players like Micron and Dell, which rose about 260%. Four of these companies supply key components for AI infrastructure, incl...
SpaceX has increased its revolving credit facility from $1.5 billion to $5 billion, a 233% rise, just before its IPO. This move significantly enhances the company's financial flexibility, suggesting it is preparing for large investments in projects l...
Suntex Enterprises completed the acquisition of 100 acres in South Texas for approximately $2.5 million through its subsidiary Red Spur Land & Ranch Co. This land purchase marks the start of a multi-phase mixed-use development project including resid...
